This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Aug. 8, 2012 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr.
Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 2012 Wedbush PacGrow Lifesciences Management Access Conference. The presentation is scheduled for
Wednesday, August 15, 2012 at
9:45 a.m. Eastern Time, at the Le Parker Meridien in New York City.
Dr. Sirgo will focus on BDSI's progress with the clinical development program and the market opportunity for BEMA Buprenorphine/Naloxone (BNX) for the treatment of opioid dependence. Additionally, Dr. Sirgo will discuss BDSI's worldwide licensing and development agreement with Endo Heath Solutions (Endo) for BEMA Buprenorphine for the treatment of chronic pain and the recently initiated Phase 3 clinical program.
The presentation will be webcast live and can be accessed at
www.bdsi.com. For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.
About BioDelivery Sciences International
BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction. BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology. ONSOLIS (fentanyl buccal soluble film) is approved in the U.S.,
Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer. The commercial rights are licensed to Meda for all territories worldwide except for
Taiwan (licensed to TTY Biopharm) and
South Korea (licensed to Kunwha Pharmaceutical Co.). BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation with naloxone for the treatment of opioid dependence. BEMA Buprenorphine for chronic pain is licensed on a worldwide basis to Endo. BDSI's headquarters is located in
Raleigh, North Carolina. For more information, visit
® and BEMA
® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS
® is a registered trademark of Meda Pharmaceuticals, Inc. BREAKYL
™ is registered trademark of Meda Pharma GmbH & Co. KG.